Trial · NCT02526017
Adverse events6,208
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 6,208
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 2 mg/kg Q2W | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 4 mg/kg Q2W | 3 | 11 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 6 mg/kg Q2W | 0 | 10 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 1mg/kg + Nivolumab 3 mg/kg Q2W | 2 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 2 mg/kg + Nivolumab 3 mg/kg Q2W | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1a+1b: Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W | 88 | 265 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 6 mg/kg + Nivolumab 3 mg/kg Q2W | 3 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q3W | 1 | 10 | |
| other | Anaemia of chronic disease | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 2 mg/kg Q2W | 0 | 3 | |
| other | Anaemia of chronic disease | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 4 mg/kg Q2W | 0 | 11 | |
| other | Anaemia of chronic disease | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 6 mg/kg Q2W | 0 | 10 | |
| other | Anaemia of chronic disease | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 1mg/kg + Nivolumab 3 mg/kg Q2W | 0 | 4 | |
| other | Anaemia of chronic disease | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 2 mg/kg + Nivolumab 3 mg/kg Q2W | 0 | 3 | |
| other | Anaemia of chronic disease | Blood and lymphatic system disorders | Phase 1a+1b: Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W | 1 | 265 | |
| other | Anaemia of chronic disease | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 6 mg/kg + Nivolumab 3 mg/kg Q2W | 0 | 6 | |
| other | Anaemia of chronic disease | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q3W | 0 | 10 | |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 2 mg/kg Q2W | 0 | 3 | |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 4 mg/kg Q2W | 0 | 11 | |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 6 mg/kg Q2W | 0 | 10 | |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Phase 1a: Cabiralizumab 1mg/kg + Nivolumab 3 mg/kg Q2W | 0 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02526017/events